Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Ardelyx, Inc.

ARDX ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: STRONG BUY

Last Close

$3.13

▼ -2.49%

Market Cap $779.96M · Vol 886.06K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: 19.08

Market Cap

$779.96M

Small Cap

Div Yield

N/A

EPS Growth

+31.82%

YoY

RSI (14)

36.56

Momentum

Beta

0.76

vs Market

52W High

$8.40

61.79% below

52W Low

$3.06

5.07% above

Volume

886.06K

Avg 1.45M

P/B

8.53

Price-to-book

ROE

-36.21%

Return on equity

Free Float

96.00%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Ardelyx, Inc. (ARDX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ARDX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.88%

-10.57%

-38.51%

-47.48%

YTD

-46.31%

-40.83%

-12.08%

+163.03%

Financials & Valuation

TTM · Annual

Total Revenue	$407.32M
Net Income	$-61,599,000.00
Revenue Growth (YoY)	+23.77%
Gross Margin	90.29%
Operating Margin	-10.06%
Net Profit Margin	-15.12%
ROE	-36.21%
ROA · ROIC	-12.94% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	19.08
PEG Ratio	N/A
P/S	3.45
P/B	8.53
P/FCF	N/A
EPS Growth	+31.82%
Outstanding Shares	249.19M

Technical Indicators

50-Day SMA	$3.55
200-Day SMA	$5.46
RSI (14)	36.56
Beta	0.76
52-Week High	$8.40
52-Week Low	$3.06

Volume Today	886.06K
Avg Daily Volume (30D)	1.45M
Relative Volume	0.61x
Volatility (10D)	43.85
Volatility (30D)	35.97
Free Float	96.00%

Analyst Consensus

STRONG BUY

Current Price $3.13

Mean Target $12.88

52W Low$3.06 52W High$8.40

Current

Target

$3.06 $8.40

Current Analyst target

+311.56% upside potential · 11 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001WH4F33

ISINUS0396971071

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -0.25% ARGX.BR argenx SE +0.82% ARGX argenx SE +2.34% 2269.HK WuXi Biologics (Cayman) Inc. -1.30% GMAB Genmab A/S +1.28%

Company Profile

Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas.